The awkward moment in a startup’s life can arrive after the celebration. The money is in the bank. The product works. Somewhere inside a large employer or insurance company sits a person who might buy it. Getting to that person, however, is a different business from writing software.
SemperVirens VC has organized an investment firm around that distance. It backs companies in healthcare, financial services, and the workforce, then helps them navigate the people and institutions between an invention and a purchase. Its proposition is unusually practical: a useful investor should help a company sell.
- Capital comes with introductions to buyers and distribution partners.
- The accelerator works with small cohorts of four companies.
- The emerging AI thesis favors businesses that take responsibility for completed work.
01 / The buyer is part of the product
Consider the portfolio. Human Interest provides retirement plans for smaller businesses. Ashby builds recruiting software. Stepful trains people for entry-level healthcare careers. Midi Health delivers specialized women’s care. These companies occupy different categories, yet their routes to adoption can involve overlapping employers, benefits decisions, and institutional relationships.
That overlap explains SemperVirens’ position in the market. A specialist investor can learn which problem a buyer recognizes, which budget might cover it, and which existing partner already has permission to enter the room. The firm’s expertise sits in that commercial detail: pricing, positioning, buyer feedback, and routes through established platforms.
There is a concrete example. When ADP launched its corporate venture fund in October 2023, it announced a partnership with SemperVirens. ADP brought its customers, platforms, and subject expertise; SemperVirens brought an advisory board then described as more than 140 experts. The relationship joined a startup’s need for reach with a large company’s search for useful innovation.
02 / Follow the money to the channel
In March 2025, SemperVirens announced $177 million across two new funds. Core Fund III received $141 million for early-stage investments. Growth Opportunity Fund II received $36 million for growth investments in strong portfolio companies. These are pools of investment capital, with different jobs to do.
Early stage
Growth stage
The limited partners included Paychex, ADP Ventures, The Cigna Group Ventures, Guardian, MetLife, and Unum, alongside other investors. Read that list as a map of payroll, insurance, and benefits. Some organizations supplying capital also understand the markets a portfolio company needs to enter. That creates the possibility of advice with a route to implementation.
SemperVirens manages funds that invest in private businesses. Founders receive capital and commercial help; limited partners seek investment returns. The operating work matters because a company that finds repeatable demand has a better chance of becoming valuable. An introduction is useful only if something commercially durable follows it.
03 / A cohort small enough to know
The accelerator, announced in June 2025, formalized an earlier part of that journey. Its first cohort contained Clasp, Sunny Health AI, Outro, and Onboarded. The launch targeted companies from pre-seed through Series A, especially those selling to employers, brokers, payers, carriers, healthcare systems, and human-capital platforms.
The current program describes cohorts of four, customized around target buyers. Founders receive individual feedback, help sharpening distribution, and access to industry gatherings. A built-in investment component connects the program to the firm’s capital. It is a hands-on route through a particular buying environment.
“We moved from prospecting to pipeline in a matter of months.”
Kevin Riley, founder and CEO of actAVA, in a testimonial on the accelerator website
What did that support cost? A June 2025 interview described typical SemperVirens investment checks of $1 million to $5 million, with smaller commitments possible between rounds. Those figures describe capital going into companies. A founder evaluating participation still has to assess the investment agreement, dilution, time commitment, and commercial fit.
The practical lesson travels beyond an accelerator application. Identify the person who owns the problem. Learn how they buy. Find the intermediary they already trust. Test whether that intermediary has a reason to help. The sequence is simple enough to copy; earning those relationships takes considerably longer.
04 / The pilot collection problem
Access alone cannot repair confused purchasing. In a February 2026 essay, SemperVirens investor Amanda Paolino described conversations with insurance executives under pressure to adopt AI. One carrier had hired several vendors for the same workflow. Experimentation had arrived before a coherent operating plan.
Here was an early point of failure: fragmented tools and duplicated effort made the return harder to understand. This was a reported buyer problem, rather than a confession about a failed SemperVirens investment. It helps explain why the firm looks for founders who understand the work beneath the demonstration.
By July, Paolino’s published framework emphasized AI businesses that could take on existing service work. The attraction was an approved budget for something a customer already needed done. The essay presented this as a continuation of earlier investments in technology-enabled services, with AI expanding how much work software could perform.
05 / What happens after the introduction
That argument has conditions. A service business needs improving economics as it grows. A healthcare buyer still needs clinical credibility; an insurer still needs reliable execution. A consumer startup whose customers never pass through these institutional channels may gain less from this particular network. Distribution has to match the business.
SemperVirens’ homepage now reports more than 5,500 customer introductions and over $200 million in directly influenced annual recurring revenue. These are the firm’s own ecosystem measures, describing portfolio activity rather than its management-company sales. They frame the question founders should bring to any investor meeting: what happened after the introductions?
The revealing idea is that venture support can be organized around purchasing. Buyers give feedback, partners offer routes to market, and capital helps a company keep moving while it learns. For a founder staring at a working product and an empty pipeline, that is a sensible place to begin.